BidaskClub upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a strong sell rating to a sell rating in a report issued on Wednesday morning.

INO has been the topic of a number of other research reports. Citigroup assumed coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a buy rating and a $10.00 price target on the stock. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, November 28th. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, November 13th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday. Finally, Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $19.16.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at $5.05 on Wednesday. The firm has a market capitalization of $463.67, a P/E ratio of -4.21 and a beta of 2.75. Inovio Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). The business had revenue of $2.60 million for the quarter, compared to the consensus estimate of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business’s quarterly revenue was down 79.2% on a year-over-year basis. During the same period last year, the firm posted ($0.28) EPS. sell-side analysts predict that Inovio Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of INO. Wasatch Advisors Inc. grew its position in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares during the last quarter. Allianz Asset Management GmbH grew its position in Inovio Pharmaceuticals by 12.4% in the third quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock worth $1,412,000 after buying an additional 24,652 shares during the last quarter. OxFORD Asset Management LLP grew its position in Inovio Pharmaceuticals by 410.3% in the third quarter. OxFORD Asset Management LLP now owns 126,404 shares of the biopharmaceutical company’s stock worth $799,000 after buying an additional 101,633 shares during the last quarter. Vanguard Group Inc. grew its position in Inovio Pharmaceuticals by 4.2% in the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after buying an additional 129,164 shares during the last quarter. Finally, First Interstate Bank grew its position in Inovio Pharmaceuticals by 291.9% in the third quarter. First Interstate Bank now owns 24,300 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 18,100 shares during the last quarter. Institutional investors and hedge funds own 32.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals (INO) Stock Rating Upgraded by BidaskClub” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/inovio-pharmaceuticals-ino-stock-rating-upgraded-by-bidaskclub/1827692.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.